ReviewBiomimetics (Basel, Switzerland)2025
Nanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier.
Review in Biomimetics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on mRNA drug delivery strategies in the nervous system.Nanomedicine (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningitis is the acute or chronic inflammation of the protective membranes, surrounding the brain and spinal cord, and this inflammatory process spreads throughout the subarachnoid space. The traditional drug delivery methods pose a disadvantage in limiting the capacity of crossing the blood-brain barrier (BBB) to reach the central nervous system (CNS). Hence, it is imperative to develop novel approaches that can overcome these constraints and offer efficient therapy for meningitis. Nanoparticle (NP)-based therapeutic approaches have the potential to address the limitations such as penetrating the BBB and achieving targeted drug release in specific cells and tissues. This review highlights recent advancements in nanotechnology-based approaches, such as functionalized polymeric nanoparticles, solid lipid nanoparticles (SLNs), nanostructured lipid carriers, nanoemulsions, liposomes, transferosomes, and metallic NPs for the treatment of meningitis. Recently, bionics has emerged as a next-generation technology in the development of novel ideas from biological principles, structures, and interactions for neurological and neuroinfectious diseases. Despite their potential, more studies are needed to ensure the safety and efficacy of NP-based drug delivery systems focusing on critical aspects such as toxicity, immunogenicity, and pharmacokinetics. Therefore, this review addresses current treatment strategies and innovative nanoparticle approaches, and it discusses future directions for efficient and targeted meningitis therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.